 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
|
|
| |
| Company Profile |
| |
|
Avigen, Inc., a development stage company, focuses on the development of pharmaceutical products for the treatment of serious and chronic hematological and neurological diseases using its DNA-based drug delivery technologies. Its most advanced product development programs are designed to utilize its adeno-associated virus vector technology to deliver DNA into the cells of patients in order to generate the expression of therapeutic proteins to treat hemophilia and Parkinsons disease. The companys development programs comprise Coagulin-B, a gene therapy product candidate for the treatment of hemophilia B, as well as AV201, a product candidate for the treatment of advanced Parkinsons disease. As of March 31, 2004, Coagulin-B was in phase I clinical trials and Avigen filed an investigational new drug application for AV201. The company has a collaboration agreement with Bayer Corporation. Avigen was established in 1992 and is headquartered in Alameda, California.
|
AVIGEN INC Related |
|
Avigen, Inc. Development of gene therapy products derived from adeno-associated virus ("AAV") for the treatment of inherited and acquired diseases.
|
|
Avigen Avigen has all the benefits you would expect to find from a ... send/fax resume to: Avigen, Inc. ... positions at Avigen at this time. © 2006 Avigen, Inc. ...
|
|
AVGN: Summary for Avigen, Inc. - Yahoo! Finance Get detailed information on Avigen, Inc. ... Rankings for AVIGEN INC StarMine(Wed, Oct ... AVIGEN INC (AVGN=US) 2-weeks forecast Pechala's Reports(Nov 30) ...
|
|
|
|
|
